<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="31">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04570085</url>
  </required_header>
  <id_info>
    <org_study_id>2018_95</org_study_id>
    <secondary_id>2019-002360-27</secondary_id>
    <nct_id>NCT04570085</nct_id>
  </id_info>
  <brief_title>Effect of CAFfeine on Cognition in Alzheimer's Disease</brief_title>
  <acronym>CAFCA</acronym>
  <official_title>Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Effect of a 30-week Caffeine Treatment on Cognition in Alzheimer's Disease at Beginning to Moderate Stages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupement Interrégional de Recherche Clinique et d'Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratory of excellence DISTALZ</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Région Nord-Pas de Calais, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Meo coffee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sporadic Alzheimer's disease is a multifactorial illness arising a major medico-economic&#xD;
      stakes for our aging societies. There is currently no curative treatment available.&#xD;
&#xD;
      Coffee is a complex beverage with psychostimulant properties whose main effective element,&#xD;
      caffeine, has a pleiotropic effect on the central nervous system. Caffeine pharmacological&#xD;
      properties enable its use like an Alzheimer's disease symptomatic treatment. Its supposed&#xD;
      benefits mustn't obscure anxiety and insomnia caffeine effect at large dose, which&#xD;
      Alzheimer's patients might be more vulnerable.&#xD;
&#xD;
      The main study objective is to evaluate placebo-controlled caffeine efficacy (30 treatments&#xD;
      weeks) on cognitive decline in Alzheimer's disease dementia at beginning to moderate stage&#xD;
      (MMSE 16-24).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">November 2024</completion_date>
  <primary_completion_date type="Anticipated">November 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in NTB scores</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on MMSE score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on MMSE score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on NTB subscores</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on NTB subscores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on TAP scores</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on TAP scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on Epworth score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on Epworth score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on DAD-6 score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on DAD-6 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on QoL-AD score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on QoL-AD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on CGIC score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on CGIC score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine treatment effect on Zarit score</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>difference between randomized value and value after 30 weeks of treatment on Zarit score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on MMSE score after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on MMSE score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on NTB subscores after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on NTB subscores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on TAP scores after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on TAP scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on Epworth score after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on Epworth score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on DAD-6 score after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on DAD-6 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on QoL-AD score after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on QoL-AD score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>persistent effect of caffeine treatment on Zarit score after a 6 weeks wash out period</measure>
    <time_frame>36 weeks after randomization</time_frame>
    <description>difference between value after 30 weeks of treatment and value after a 6 weeks wash out period (from Week 30 to Week 36) on Zarit score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine effect heterogeneity: impact of AD treatment</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>impact of AD treatment on caffeine effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine effect heterogeneity: impact of ApoE4 status</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>impact of ApoE4 status on caffeine effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine effect heterogeneity: impact of caffeine metabolism speed</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>impact of caffeine metabolism on caffeine effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine effect heterogeneity: impact of gender</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>impact of gender on caffeine effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine safety profile: NPI scores</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>changes in NPI scores and subscores between caffeine and placebo arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine safety profile: heart beat</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>changes in heart beat between caffeine and placebo arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine safety profile: blood pressure</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>changes in blood pressure between caffeine and placebo arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caffeine and its derivatives concentrations in blood samples</measure>
    <time_frame>30 weeks after randomization</time_frame>
    <description>increase in caffeinemia and its derivatives in the morning (fasting samples)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">248</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Caffeine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>after a 3 weeks up titration period, 1 capsule of 200 mg twice a day during 27 weeks (ie 400mg/day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>after a 3 weeks up titration period, 2 capsules per day during 27 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Caffeine</intervention_name>
    <description>100mg caffeine capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks (by 100mg stages) until 400mg aim dose per day in 2 doses during 27 weeks, and finally interrupt according to the same negative titration.</description>
    <arm_group_label>Caffeine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule treatment, beginning after caffeine diet during 6 weeks, titrate in 3 weeks until 2 doses aim dose per day during 27 weeks, and finally interrupt according to the same negative titration.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 50 at screening&#xD;
&#xD;
          -  Probable Alzheimer dementia according to the criteria of the National Institute on&#xD;
             Aging-Alzheimer's Association; diagnosis must be supported by brain imaging (CT or&#xD;
             MRI) and blood test (including ionogram, kidney and liver function, calcemia, CRP,&#xD;
             TSH, B12 vitamins and folates) performed in routine care&#xD;
&#xD;
          -  MMSE score ≥16&#xD;
&#xD;
          -  Presence of an informant and caregiver, living with the patient&#xD;
&#xD;
          -  IAChE and/or Memantine treatment non-compulsory ; If implemented it must be effective&#xD;
             and stable for 2 months before the selection visit and must remain stable for the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who refuse to adopt a low caffeine diet (eviction of tea, caffeinated sodas,&#xD;
             chocolate in large quantities)&#xD;
&#xD;
          -  Current major depressive episode according to DSM-5 criteria&#xD;
&#xD;
          -  Another chronic pathology of the central nervous system&#xD;
&#xD;
          -  Major anxiety according to the clinician (consistent with the corresponding nPI-R&#xD;
             items that must indicate a severity &gt;2 and an impact &gt;3)&#xD;
&#xD;
          -  Sleep disorders defined by severity and an impact on NPI-R; a patient fitted for OSA&#xD;
             may be included if the device has been in use for 3 months and well tolerated (stable)&#xD;
&#xD;
          -  Decompensated heart disease or severe rhythm disorder (excluding slow, treated and&#xD;
             stable chronic atrial fibrillation)&#xD;
&#xD;
          -  Active smoking&#xD;
&#xD;
          -  For childbearing women : pregnancy in progress or planned (A pregnancy test will be&#xD;
             performed)&#xD;
&#xD;
          -  Patients who take forbidden treatment :&#xD;
&#xD;
               -  Psychotropic treatments introduced or modified &lt; 2 months before inclusion&#xD;
&#xD;
               -  Chronic use of CYP1A2 inducing or inhibiting drugs&#xD;
&#xD;
               -  All caffeine-containing specialties&#xD;
&#xD;
               -  Drugs that influence caffeine metabolism&#xD;
&#xD;
               -  Drugs that may interact with caffeine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>thibaud LEBOUVIER, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thibaud LEBOUVIER, MD,PhD</last_name>
    <phone>03 20 44 60 21</phone>
    <phone_ext>+33</phone_ext>
    <email>thibaud.lebouvier@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier GODEFROY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Arras</name>
      <address>
        <city>Arras</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick LE COZ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier CNOCKAERT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Béthune</name>
      <address>
        <city>Béthune</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle LAVENU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier MARTINAUD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Calais</name>
      <address>
        <city>Calais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier DEREEPER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Dunkerque</name>
      <address>
        <city>Dunkerque</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdelghani EL AZOUZI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Le Quesnoy</name>
      <address>
        <city>Le Quesnoy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Denis LEFEBVRE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lens</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier SENECHAL, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Roger Salengro</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thibaut Lebouvier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lille consultation mémoire Les Bâteliers</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique HUVENT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Roubaix</name>
      <address>
        <city>Roubaix</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FORZY, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David WALLON, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint Quentin</name>
      <address>
        <city>Saint-Quentin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jadwiga ATTIER-ZMUDKA, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Seclin</name>
      <address>
        <city>Seclin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Véronique BERRIOT, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Tourcoing</name>
      <address>
        <city>Tourcoing</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karim GALLOUJ, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DESPREZ, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>June 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2020</study_first_posted>
  <last_update_submitted>February 10, 2022</last_update_submitted>
  <last_update_submitted_qc>February 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>caffeine</keyword>
  <keyword>cognitive impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

